Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. clinical trial pipeline

8 trials changed in the last 30 days: 0 stopped, 7 with notable changes, 1 with a minor change only.

1. Notable

   XS-03-II201 · XS-03 in Combination With FOLFOX or FOLFIRI…XS-03-II201 · XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab · Metastatic Colorectal Cancer Patients With RAS Mutation

   Sponsor changed: NovaOnco Therapeutics Co., Ltd. to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 1/2· NCT06936527· Registry history of NCT06936527 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

2. Notable

   XH-S004 Tablets · Non-cystic Fibrosis Bronchiectasis

   Sponsor changed: S-INFINITY Pharmaceuticals Co., Ltd to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

   Also in this update: Trial status changed: Not Yet Recruiting → Active, Not Recruiting

   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 2· NCT06981091· Registry history of NCT06981091 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

3. Notable

   XS-04 · Relapsed or Refractory Hematologic Malignancies

   Sponsor changed: NovaOnco Therapeutics Co., Ltd. to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 1· NCT06820268· Registry history of NCT06820268 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

4. Notable

   XH-S004 Tablet · Chronic Obstructive Pulmonary Disease (COPD) to…XH-S004 Tablet · Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations

   Sponsor changed: S-INFINITY Pharmaceuticals Co., Ltd to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

   Also in this update: Trial status changed: Not Yet Recruiting → Active, Not Recruiting

   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 1· NCT07035652· Registry history of NCT07035652 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

5. Notable

   FXS0683-001 · FXS0683 · Blood Tumors

   Recruitment opened

   Also in this update: Interventions modified

   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 1· NCT07616089· Registry history of NCT07616089 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

6. Notable

   QT Interval Effects Study of Oral FXS5626 Tablets

   Recruitment opened

   Also in this update: Study completion pushed from Sep 25, 2026 to Jan 22, 2027

   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Phase 1· NCT07695779· Registry history of NCT07695779 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

7. Notable

   XH-S003-II-102 · XH-S003 Capsules · Paroxysmal Nocturnal…XH-S003-II-102 · XH-S003 Capsules · Paroxysmal Nocturnal Hemoglobinuria

   Sponsor changed: S-INFINITY Pharmaceuticals Co., Ltd to Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.·Not applicable· NCT07657052· Registry history of NCT07657052 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.